Weekly docetaxel, cisplatin, and irinotecan (TPC): results of a multicenter phase II trial in patients with metastatic esophagogastric cancer.
about
Novel immunotherapeutic strategies of gastric cancer treatmentPhase II Study of Irinotecan and Cisplatin Combination Chemotherapy in Metastatic, Unresectable Esophageal CancerTargeted therapies for gastric cancer: current status.Treatment options in patients with metastatic gastric cancer: current status and future perspectivesChemotherapy-induced weakness and fatigue in skeletal muscle: the role of oxidative stress.Venous thromboembolism in patients receiving perioperative chemotherapy for esophagogastric cancer.
P2860
Weekly docetaxel, cisplatin, and irinotecan (TPC): results of a multicenter phase II trial in patients with metastatic esophagogastric cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 12 January 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Weekly docetaxel, cisplatin, a ...... static esophagogastric cancer.
@en
Weekly docetaxel, cisplatin, a ...... static esophagogastric cancer.
@nl
type
label
Weekly docetaxel, cisplatin, a ...... static esophagogastric cancer.
@en
Weekly docetaxel, cisplatin, a ...... static esophagogastric cancer.
@nl
prefLabel
Weekly docetaxel, cisplatin, a ...... static esophagogastric cancer.
@en
Weekly docetaxel, cisplatin, a ...... static esophagogastric cancer.
@nl
P2093
P2860
P356
P1433
P1476
Weekly docetaxel, cisplatin, a ...... static esophagogastric cancer.
@en
P2093
A Muzikansky
J A Meyerhardt
L S Blaszkowsky
M M Vincitore
P2860
P304
P356
10.1093/ANNONC/MDN658
P577
2009-01-12T00:00:00Z